Elevated 18:1 lysophosphatidylcholine contributes to neuropathic pain in peripheral nerve injury Authors: Jinxuan Ren, Lina Yu, Jiaqi Lin, Ying Liu, Longfei Ma, Yangyuxin huang, Na Sun, Yutao Deng, Da Zhong, Binglin Zhou, Baochun Jiang, Min Yan Published: 2025 ABSTRACT AbstractBackgroundNeuropathic pain is a maladaptive and chronic condition with limited effective treatments. Although recent studies have suggested that certain lipid metabolites, like lysophosphatidylcholine (LPC), may contribute to chronic pain, their specific roles and mechanisms remain unclear.ObjectiveThis study investigated the role and mechanism of LPC(18:1), a lipid subtype, in neuropathic pain caused by nerve injury.MethodsUsing a mouse model of spinal nerve ligation, LPC(18:1) levels were measured in serum, dorsal root ganglion (DRG), spinal cord (SC) and cerebrospinal fluid (CSF). Nociception was assessed using von Frey and Hargreaves’ methods, while molecular analyses explored inflammatory pathways and oxidative stress.ResultsLPC(18:1) levels significantly increased in the serum, DRG and CSF after nerve injury. Administration of LPC(18:1) induced heightened pain responses and activated inflammatory pathways, including protein kinase C (PKC) and extracellular regulated protein kinase (ERK) in the DRG, as well as glial cells in the SC. The findings suggested that oxidative stress played a role in LPC(18:1) production, and its effects were mediated by G protein-coupled receptor 132 (GPR132).ConclusionLPC(18:1) may serve as a potential biomarker and therapeutic target for managing neuropathic pain.Keywords: Analgesia, Peripheral Nerve Injuries, CHRONIC PAIN WHAT IS ALREADY KNOWN ON THIS TOPIC Neuropathic pain is a maladaptive and chronic condition with limited effective treatments. Certain lipid metabolites, like lysophosphatidylcholine (LPC), may contribute to chronic pain. Screening specific signaling lipid metabolites is regarded as new targets for treatments of neuropathic pain. Neuropathic pain is a maladaptive and chronic condition with limited effective treatments. Certain lipid metabolites, like lysophosphatidylcholine (LPC), may contribute to chronic pain. Screening specific signaling lipid metabolites is regarded as new targets for treatments of neuropathic pain. WHAT THIS STUDY ADDS Augmented LPC(18:1) played an important role in spinal nerve ligation-induced neuropathic pain. Oxidative stress induced LPC(18:1) production. LPC(18:1) induced heightened pain responses and activated inflammatory pathways, which were associated with GPR132. Augmented LPC(18:1) played an important role in spinal nerve ligation-induced neuropathic pain. Oxidative stress induced LPC(18:1) production. LPC(18:1) induced heightened pain responses and activated inflammatory pathways, which were associated with GPR132. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY LPC(18:1) will serve as a potential biomarker for predicting neuropathic pain. LPC(18:1) will serve as a potential biomarker for predicting neuropathic pain. Introduction Neuropathic pain (NP) is a common chronic pain condition with major impact on quality of life.1 Current treatment for NP individuals is inadequate and limited. Although traditional drugs, such as gabapentin and opioids, could alleviate certain symptoms of NP, they are also accompanied by various adverse effects (dizziness, nausea) and drug tolerance.2 At present, some signaling lipid metabolites act on their corresponding receptors to exert chronic pain,3 which is regarded as new targets for treatments of NP. The initiation and maintenance of chronic pain may be related to specific lipid mediators.4 Being a substrate for cyclooxygenases (COX), lipoxygenases, and cytochrome P450 family enzymes, released arachidonic acid was converted to an expanding number of known lipid mediators including prostaglandins.5 Prostaglandin E(2) acted on G-protein-coupled receptors (GPCRs), namely EP1 and EP4, which might occur in peripheral inflamed tissues, playing a role in the inflammatory pain.6 Cytochrome P450-derived linoleic acid (LA) metabolites 9,10-epoxyoctadecenoic acid (9,10-EpOME) contributed to peripheral sensitization in the paclitaxel-induced NP.7 Besides, sphingosine-1-phosphate (S1P) was a sphingolipid metabolite that served as a potent extracellular signaling molecule, that had a causative role in cancer-induced bone pain by binding to the S1P receptor 1 (S1PR1).8 Thus, new insights into the mechanisms leading to the development of nerve injury-induced NP pointed to systemic imbalances in metabolites of lipids.9 We previously identified lysophosphatidylcholine (LPC) accounted for the most pronounced alterations with significant changes by metabolomics in spinal nerve ligation (SNL) mice. Pain-related diseases such as Complete Freund’s adjuvant injection, skin incision, chemotherapy-induced peripheral neuropathy, sickle cell disease, and migraine were all accompanied by elevated levels of LPC.10 LPC was classified into various subtypes based on the length of carbon chains and the position of double bonds, which varied in different disease models. The elevated LPC(16:0) in the synovial fluid of patients could be considered a trigger for chronic joint pain.11 LPC(20:3) in serum of fibromyalgia patients or mice was also upregulated.12 LPC(26:0) and LPC(28:1) were associated with multisite musculoskeletal pain. Therefore, screening for specific LPC subtypes in NP is also crucial for the prediction and treatment. Collectively, we highlighted the involvement of LPC(18:1) in the nerve injury-induced NP. The exogenous injection of LPC(18:1) induced mechanical and thermal hyperalgesia. In addition, we analyzed the synthesis process of LPC(18:1) in SNL. We have shown that G protein-coupled receptor 132 (GPR132) was associated with LPC(18:1)-induced chronic hyperalgesia via facilitating protein kinase C (PKC)/extracellular regulated protein kinase (ERK) pathway. Hence, this study explored the role and mechanism of LPC(18:1) in NP, thus expecting to be a new biomarker for predicting or targeting treatment of NP. Materials and methods Animals C57BL/6 mice (male and female, aged 6–8 weeks) were purchased from Nanjing Institute of Biomedicine. All animals were maintained on a 12:12 light-dark cycle, freely accessing food and water. These animals were divided into different groups randomly (online supplemental figure 1). We have been very careful to ensure the welfare of rodents and have kept their use to a minimum. Reagents LPC(18:1) was purchased from Avanti Polar Lipids (845875P), which was dissolved in ethanol and diluted in saline to reach the appropriate concentration (10 µM and 50 µM for subcutaneous injection, 5 µg and 15 µg for intrathecal (i.t.) injection). Mice received a daily intraperitoneal (i.p.) injection of darapladib (10 mg/kg; 366057-34-6, Cayman, USA), Tempol (100 mg/kg; 176141, Sigma-Aldrich, USA) + NAC (200 mg/kg; PHR1098, Sigma-Aldrich, USA) on day 1 postsurgery separately. Mice received i.t. injection of Go6976 (20 µM; HY-10183, MCE, USA) or U0126 (12.5 nmol; 19-147, Sigma-Aldrich, USA) after the administration of LPC(18:1). Surgery We used the L4 SNL model in which the left L4 spinal nerve was exposed, isolated, and tightly ligated with 6–0 silk thread.1 For sham operations, the left L4 spinal nerve was exposed without ligation. Behavioral testing Spontaneous pain testing Animals were arranged to adapt to the testing environment for 3 days before testing. The behavioral tests were done by the observers blinded to the treatment. The activity of all mice within 1 hour was recorded using a camera after subcutaneous injection of 50 µM LPC(18:1) into the left posterior plantar area of mice. The number and duration of licking feet in mice every 5 min were used as indicators to reflect the spontaneous pain behavior. Von Frey testing For testing mechanical allodynia, the plantar surface of the left hindpaw was stimulated with 0.07 g and 0.4 g von Frey filaments with 10 stimulation trials for each, which was recorded according to the frequency of the withdrawal response. Data were aggregated and calculated as a percentage to get the paw withdrawal frequencies (PWFs). Hargreaves test For testing heat sensitivity, paw withdrawal latencies (PWLs) were tested by radiant heat using the Hargreaves method (IITC Life Science). The time was recorded as withdrawal latency from the start of irradiation to withdrawal of the left hind paw with a cut-off of 20 s, which was repeated at 5 min intervals. The average of three times was regarded as the PWL result. Statistical analysis All data are denoted as mean±SEM. GraphPad Prism V.8 is applied to analyze all statistical data. All the results were analyzed using two-tailed Student’s t-test, one-way analysis of variance (ANOVA) with the Tukey’s post hoc test, two-way ANOVA followed by the post hoc Tukey test (more than two groups) or Bonferroni’s test (two groups). A p<0.05 was regarded as statistically significant. Results Nerve injury increased LPC(18:1) level We observe that LPC accounts for the most numerous alterations in the serum of SNL mice on day 7 (figure 1A). Among the detected lipids, LPC(18:1) was an eligible candidate (figure 1B–D). Relative abundance of the analyte with m/z 522.4–184.1, as a potential match for LPC(18:1) (figure 1E). Besides, the LPC(18:1) level in the dorsal root ganglion (DRG) significantly increased after nerve injury (figure 1F), with no change in the spinal cord (SC) (figure 1G). Importantly, LPC(18:1) level in the cerebrospinal fluid (CSF) was upregulated (figure 1H). Taken together, these results suggested that the upregulation of LPC(18:1) may play an important role in SNL-induced NP. LPC(18:1) exhibited an increase after nerve injury. (A) Distribution of glycerophos-phocholines species after nerve injury. (B) The content of different LPC species in the serum after nerve injury. (C) The content of LPC(18:1) in the serum of mice on day 7 of SNL. Data are mean±SEM (n=8 mice/group). Student’s t-test. *p<0.05, **p<0.01 compared with the Sham group. (D) The chemical structural formula of LPC(18:1). (E) The metabolic features of LPC(18:1). (F) The content of LPC(18:1) in the DRG of SNL mice on day 7. (G) The content of LPC(18:1) in the SC of SNL mice on day 7. (H) The content of LPC(18:1) in the CSF of SNL mice on day 7. Data are mean±SEM (n=3 mice/group). Student’s t-test. *p<0.05 compared with the Sham group. CSF, cerebrospinal fluid; DRG, dorsal root ganglion; LPC, lysophosphatidylcholine; SC, spinal cord; SNL, spinal nerve ligation. LPC(18:1) injection induced pain-related behavior To explore the role of LPC(18:1) in pain-related behavior, 10 µM and 50 µM of LPC(18:1) were applied into the dorsum of the male mice paw subcutaneously (online supplemental figure 2A,2B). 50 µM LPC(18:1) induced increase in the number and sum time of licking in the mice (figure 2A, B). Besides, different doses of LPC(18:1) with single administration led to heat hyperalgesia and mechanical allodynia without sex differences (figure 2C–E, online supplemental figure 3G-I). LPC(18:1) with repeated administration prolonged mechanical allodynia and heat hyperalgesia without sex differences (figure 2F–H, online supplemental figure 3J-L). There were no differences in PWFs and PWLs on the contralateral side of male mice (online supplemental figure 3A-F). To observe the effect of different administration approaches of LPC(18:1), 5 µg and 10 µg of LPC(18:1) were applied for i.t. administration (online supplemental figure 2C). LPC(18:1) increased PWFs and decreased PWLs in both male (figure 2I–K) and female mice (online supplemental figure 3M-O). These results demonstrated that exogenous injection of LPC(18:1) induced pain-related behavior. LPC(18:1)-induced mechanical allodynia and heat hyperalgesia in naive male mice. (A, B) 50 µM LPC(18:1) injected intraplantarly induces the upregulation of the number (A) and sum time (B) of licking. Data are mean±SEM (n=6 mice/group). Two-way ANOVA followed by post hoc Bonferroni’s test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 compared with vehicle group. (C–E) Different doses of LPC(18:1) with single intraplantar administration increased the 0.07 g (C) and 0.4 g (D) PWF and reduced the PWL (E) in male mice. (F–H) Different doses of LPC(18:1) with repeated administration increased the 0.07 g (F) and 0.4 g (G) PWF and reduced the PWL (H) in male mice. (I–K) Intrathecal injection of LPC(18:1) increased the 0.07 g (I) and 0.4 g (J) PWF and decreased the PWL (K) in male mice. Data are mean±SEM (n=6 mice/group). Two-way ANOVA followed by post hoc Tukey test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 compared with vehicle group; #p<0.05, ####p<0.0001 compared with 10 µM group. Arrows in (A–K) indicated the time of LPC(18:1) administration. ANOVA, analysis of variance; BL, baseline; LPC, lysophosphatidylcholine; PWF, paw withdrawal frequency; PWL, paw withdrawal latency. LPC(18:1) activated primary sensory neurons and SC glial cells To further clarify the involvement of LPC(18:1) in the NP, we observed a neuronal activation marker pERK. Single and repeated injection subcutaneously of LPC(18:1) both increased pERK in the DRG (figure 3A–D). i.t. injection of LPC(18:1) improved the pERK level (online supplemental figure 4A.4B), and inflammatory factors (IL-1β, interleukin-1β; TNF-α, tumor necrosis factor-α) in the DRG (figure 3E,F). The occurrence of NP was associated with activation of glial cells from the dorsal horn of the SC, results from the immunofluorescence demonstrated that single injection subcutaneously of LPC(18:1) had no effect on the IBA-1 (Ionized calcium binding adaptor molecule-1, a marker of microglia) and GFAP (Glial fibrillar acidic protein, a marker of astrocyte) (online supplemental figure 4C,4D). However, repeated administration of LPC(18:1) upregulated IBA-1 (figure 3G, H), and GFAP (figure 3I, J). Besides, there is no significant difference in protein gene product 9.5 (PGP9.5) staining after LPC(18:1) treatment (online supplemental figure 4E and F). LPC(18:1) activated nociceptive primary sensory neurons in the DRG and glia cells in the spinal cord. (A) Western blot result of pERK in L3-5 DRG at 2 hours after single administration of LPC(18:1) into the mice paw subcutaneously. (B) Quantitative analysis of expression of pERK in L3-5 DRG at 2 hours. (C) Western blot result of pERK in L3-5 DRG on day 2 after repeated administration of LPC(18:1) into the mice paw subcutaneously. (D) Quantitative analysis of expression of pERK in L3-5 DRG on day 2. (E) Quantitative analysis of expression of Il1b mRNA on day 7 after intrathecal administration of LPC(18:1). (F) Quantitative analysis of expression of Tnf mRNA on day 7 after intrathecal administration of LPC(18:1). (G) Representative imaging of IBA-1 expression of spinal dorsal horn in vehicle, LPC(18:1) 10 µM and 50 µM repeated intraplantar injection mice on day 2. Scale bar, 100 µm. (H) Quantitative analysis of IBA-1 expression in the spinal dorsal horn on day 2. (I) Representative imaging of GFAP expression of spinal dorsal horn in vehicle, LPC(18:1) 10 µM and 50 µM repeated intraplantar injection mice on day 2. Scale bar, 100 µm. (J) Quantitative analysis of GFAP expression in the spinal dorsal horn on day 2. Data are mean±SEM (n=3 mice/repeat/group). One-way ANOVA with the Tukey’s post hoc test. *p<0.05, **p<0.01, ***p<0.001 compared with vehicle group; ##p<0.01 compared with 5 µg group. ANOVA, analysis of variance; DRG, dorsal root ganglion; LPC, lysophosphatidylcholine. LPC-synthesizing phospholipase A2 involved in SNL-induced LPC(18:1) As shown in figure 4A, LPC is mainly derived from the catalysis of PC by phospholipase A2 (PLA2). Next, we analyzed the expression of LPC’s metabolic enzymes. The mRNA levels of LPC-synthesizing Pla2 group 2 E (Pla2g2e) and platelet activating factor acetyl hydrolase (PAF-AH, Pla2g7) were improved in the DRG of SNL mice (figure 4B,C). Besides, darapladib (Dab, a selective PAF-AH inhibitor) once daily (10 mg/kg; i.p.) significantly prevented pain responses (online supplemental figure 2D, figure 4D–F), and the LPC(18:1) level was on a downward trend after treatment with darapladib (figure 4G). The production of LPC(18:1) depended on the increase of LPC-synthesizing enzyme in SNL model. (A) The enzymatic pathways of LPC synthesis. (B, C) mRNA levels of Pla2g2e (B) and Pla2g7 (C) on day 7 in the DRG of SNL model. Data are mean±SEM (n=3 mice/repeat/group). Student’s t-test. ***p<0.001, ****p<0.0001 compared with Sham group. (D–F) Mice received a daily intraperitoneal (i.p.) injection of darapladib (10 mg/kg) on day 1 postsurgery. The effect of darapladib on the SNL-induced mechanical allodynia (D, E) and heat hyperalgesia (F). Data are mean±SEM (n=6 mice/group). Two-way ANOVA followed by post hoc Tukey test. *p<0.05, **p<0.01, ***p<0.001 compared with SNL group. (G) The effect of darapladib on LPC(18:1) level in the DRG of SNL mice. Red arrows in (D–F) indicated the time of SNL model. Black arrows in (D–F) indicate the time of darapladib administration. ANOVA, analysis of variance; BL, baseline; DRG, dorsal root ganglion; SNL, spinal nerve ligation. LPC(18:1) resulting from oxidative stress and lipid oxidation inflicted SNL-induced NP LPC metabolism could be synthetized as consequences of oxidative stress and lipid oxidation.13 We used oxidative stress fluorescent indicators (CM-H2DCFDA) to detect the reactive oxygen species (ROS) in DRG. The ROS fluorescence level was upregulated in the DRG (figure 5A,B). Lipid oxidation was assessed by malondialdehyde (MDA) level. MDA content was increased (figure 5C). i.p. injected antioxidants (N-acetylcysteine and Tempol) relieved NP (online supplemental figure 2E, figure 5D–F), inhibited the ROS level (figure 5G,H) and reduced LPC(18:1) in the DRG (figure 5I). To identify the cellular origin of LPC(18:1), both neuronal and glial cultures were stimulated with PLA2 (two units) for 45 min (figure 5J) and observed that LPC(18:1) change in neuronal cultures was significantly higher than in glial cultures (figure 5K). These results demonstrated that LPC(18:1) may originate from neurons due to the increase of oxidative stress and lipid oxidation after nerve injury. Oxidative stress and lipid oxidation were associated with the production of LPC(18:1) in the SNL model. (A) Representative imaging of ROS expression in DRG in sham and SNL groups on day 7. Tissue ROS levels were measured by CM-H2DCFDA staining. Scale bar, 100 µm. (B) Quantification of ROS expression in DRG of mice on day 7. (C) Quantification of MDA level in DRG of mice. Data are mean±SEM (n=3 mice/repeat/group). Student’s t-test. *p<0.05, **p<0.01 compared with the Sham group. (D–F) Mice received a daily tempol (100 mg/kg) and NAC (200 mg/kg) on day 1 postsurgery. The effect of tempol and NAC on the SNL-induced mechanical allodynia (D, E) and heat hyperalgesia (F). Data are mean±SEM (n=6 mice/group). Two-way ANOVA followed by post hoc Tukey test. **p<0.01, ***p<0.001, ****p<0.0001 compared with SNL group. (G) Representative imaging of ROS expression in DRG on day 7 after the treatment of antioxidants. Scale bar, 100 µm. (H) Quantification of ROS expression in DRG on day 7 after the treatment of antioxidants. Data are mean±SEM (n=3 mice/repeat/group). Student’s t-test. *p<0.05 compared with SNL group. (I) The effect of tempol and NAC on LPC(18:1) level in the DRG on day 7 after the treatment of tempol and NAC. Data are mean±SEM (n=3 mice/repeat/group). One-way ANOVA with the Tukey’s post hoc test. *p<0.05 compared with SNL group. (J) Flow chart of PLA2 intervention in neurons and glial cells. (K) Quantification of LPC(18:1) level in neurons and glial cells after PLA2 intervention for 45 min. Data are mean±SEM (n=3 biological repeats). Student’s t-test. *p<0.05 compared with the vehicle group. Red arrows in (D–F) indicate the time of the SNL model. Black arrows in (D–F) indicate the time of tempol and NAC administration. ANOVA, analysis of variance; BL, baseline; DRG, dorsal root ganglion; LPC, lysophosphatidylcholine; SNL, spinal nerve ligation. GPR132 was involved in the development and maintenance of LPC(18:1)-induced NP Previous studies have shown the GPCR serves as LPC’s effector, such as GPR132 and GPR4.14 To investigate the roles of these two receptors in LPC(18:1)-induced NP, we first examined their changes in SNL model. We found a significant upregulation of GPR132 mRNA and protein in the DRG of SNL mice (figure 6A–C), while GPR4 mRNA remained unchanged (figure 6A). Then, we screened the Gpr132 siRNA efficary, among which siRNA3 showed the best knockdown efficacy in vitro (online supplemental figure 5A). i.t. injection of GPR132 siRNA3 (5 µg/10 µl) attenuated SNL-induced NP (figure 6D–I), decrease GPR132 expression in the DRG (online supplemental figure 5B and C) with no significant change in the SC (Supplematery online supplemental figure 5D and E). The pERK protein and Il1b and Tnf mRNA level in the DRG were also inhibited by GPR132 siRNA (figure 6J–L). Besides, i.t. injection of LV-shRNA-Gpr132 exhibited reduced mechanical allodynia and thermal hyperalgesia (online supplemental figure 5F-K). GPR132 participated in neuropathic pain caused by SNL. (A) Quantitative analysis of expression of GPR132 and GPR4 mRNA in DRG of SNL mice on day 7. Data are mean±SEM (n=3 mice/repeat/group). Student’s t-test. **p<0.01 compared with the Sham group. (B) Western blot result of GPR132 in the DRG of SNL mice on day 7. (C) Quantitative analysis of expression of GPR132 in DRG on day 7. Data are mean±SEM (n=3 mice/repeat/group). One-way ANOVA with the Tukey’s post hoc test. *p<0.05, **p<0.01 compared with day 0 group. (D–F) The effect of GPR132 siRNA in the development of SNL-induced neuropathic pain after intrathecal injection of GPR132 siRNA3 from days 1 to 3 after SNL. (G–I) The effect of GPR132 siRNA in the maintenance of SNL-induced neuropathic pain after GPR132 siRNA3 injected into the mice day 7 and 8 days after SNL. Two-way ANOVA followed by post hoc Tukey test. Data are mean±SEM (n=6 mice/group). Two-way ANOVA followed by post hoc Tukey test. *p<0.05, **p<0.01, ***p<0.001 compared with SNL+Scram. (J) Western blot result of pERK, ERK and GAPDH in the DRG on day 5 after the intervention of GPR132 siRNA. (K) Quantitative analysis of expression of pERK in DRG on day 5 after the intervention of GPR132 siRNA. (L) Quantitative analysis of expression of Il1b and Tnf mRNA in DRG on day 5 after the intervention of GPR132 siRNA. Data are mean±SEM (n=3 mice/repeat/group). One-way ANOVA with the Tukey’s post hoc test. *p<0.05, **p<0.01, ***p<0.001 compared with sham+Scram; #p<0.05, ##p<0.01 compared with SNL+Scram. Red arrows in (D–I) indicate the time of the SNL model. Black arrows in (D–I) indicate the time of siRNA administration. ANOVA, analysis of variance; BL, baseline; DRG, dorsal root ganglion. Next, we investigated the effect of GPR132 in LPC(18:1)-induced NP. GPR132 siRNA3 was administered on days 1 to 3 after i.t. LPC(18:1) and relieved mechanical allodynia and thermal hyperalgesia (figure 7A–C). Also, LV-shRNA-Gpr132 supported on 3 days before LPC(18:1) alleviated pain response (figure 7D–F). GPR132 siRNA3 downregulated the expression of GPR132 and pERK (figure 7G–I), reduced LPC(18:1)-induced Il1b and Tnf mRNA in the DRG (figure 7J). However, GPR4 siRNA had no effect on LPC(18:1)-induced NP (online supplemental figure 6A-D). Therefore, these results indicated that GPR132 regulated ERK and inflammatory factors in the SNL or LPC(18:1)-induced NP. GPR132 was associated with LPC(18:1)-induced neuropathic pain. (A–C) GPR132 siRNA3 was administrated on days 1–3 after intrathecal injection of LPC(18:1). The effect of GPR132 siRNA on the LPC(18:1)-induced mechanical allodynia (A, B) and heat hyperalgesia (C). (D–F) The effect of GPR132 shRNA on the LPC(18:1)-induced mechanical allodynia (D, E) and heat hyperalgesia (F) after LV-shRNA-Gpr132 supported on 3 days before LPC(18:1). Data are mean±SEM (n=6 mice/group). Two-way ANOVA followed by post hoc Bonferroni’s test. *p<0.05, **p<0.01 compared with LPC(18:1)+Scram group. (G) Western blot result of GPR132, pERK, ERK and GAPDH in the DRG on day 5 after the treatment of GPR132 siRNA and LPC(18:1). (H) Quantitative analysis of expression of GPR132 in the DRG on day 5 after the treatment of GPR132 siRNA and LPC(18:1). (I) Quantitative analysis of expression of pERK in the DRG on day 5 after the treatment of GPR132 siRNA and LPC(18:1). (J) Quantitative analysis of expression of Il1b and Tnf mRNA in the DRG on day 5 after the treatment of GPR132 siRNA. Data are mean±SEM (n=6 mice/group). Student’s t-test. *p<0.05, **p<0.01 compared with LPC(18:1)+Scram group. Red arrows in (A–F) indicate the time of LPC(18:1) intervention. Black arrows in (A–F) indicate the time of siRNA or shRNA administration. ANOVA, analysis of variance; BL, baseline; DRG, dorsal root ganglion; LPC, lysophosphatidylcholine. PKC-ERK acts as a downstream signaling pathway for LPC(18:1)-induced NP How did GPR132 regulate pERK? LPC interacts with GPR132 to activate PKC in myocardial cells.15 PKC participates in the phosphorylation of ERK, which is related to NP.16 To explore the effect of PKC, first we have shown that LPC(18:1) upregulated the pPKC level in the DRG (figure 8A,B), which was inhibited by the GPR132 siRNA3 (figure 8C,D). PKC inhibitor Go6976 inhibited LPC(18:1)-induced pain (online supplemental figure 2F, figure 8E–G). Go6976 also reduced the expression of pPKC and pERK (figure 8H–J). To investigate whether ERK activity participates in the LPC(18:1)-induced hyperalgesia effects, we selected U0126 as ERK inhibitor. Then, U0126 was injected intrathecally before the first LPC(18:1) injection into the mice paw subcutaneously (online supplemental figure 2G) and prevented the LPC(18:1)-induced acute hyperalgesia, and also impeded the chronic hyperalgesia induced by second LPC(18:1) injection (figure 8K–M), and downregulated pERK expression in DRG (figure 8N,O). These results suggested that PKC/ERK may act as a downstream signaling pathway for LPC(18:1)-induced NP. PKC-ERK was involved in LPC(18:1)-induced neuropathic pain. (A) Western blot result of pPKC, PKC and GAPDH in the DRG of mice treated with single intraplantar administration of LPC(18:1) at 2 hours. (B) Quantitative analysis of expression of pPKC in DRG at 2 hours. Data are mean±SEM (n=3 mice/repeat/group). One-way ANOVA with the Tukey’s post hoc test. *p<0.05 compared with vehicle. (C) Western blot result of pPKC, PKC, and GAPDH on day 5 in the DRG of mice treated intrathecally with LPC(18:1) and GPR132 siRNA. (D) Quantitative analysis of expression of pPKC in DRG on day 5. Data are mean±SEM (n=3 mice/repeat/group). Student’s t-test. *p<0.05 compared with LPC(18:1) + Scram. (E–G) Mice received intrathecal (i.t.) injection of Go6976 (20 µM) after the administration of LPC(18:1). The effect of PKC inhibitor Go6976 on the LPC(18:1)-induced mechanical allodynia (E, F) and heat hyperalgesia (G). Data are mean±SEM (n=6 mice/group). Two-way ANOVA followed by post hoc Bonferroni’s test. *p<0.05, **p<0.01 compared with LPC(18:1) + vehicle. (H) Western blot result of pPKC, PKC, pERK, ERK and GAPDH in the DRG at 6 hours after the i.t. intervention of Go6976. (I, J) Quantitative analysis of expression of pPKC (I) and pERK (J) in DRG at 6 hours after the intervention of Go6976. Data are mean±SEM (n=6 mice/group). Student’s t-test. *p<0.05 compared with LPC(18:1)+vehicle. (K–M) U0126 (12.5 nmol) was injected intrathecally before the first LPC(18:1) injection into the mice paw subcutaneously. The effect of ERK inhibitor U0126 on the LPC(18:1)-induced mechanical allodynia (K, L) and heat hyperalgesia (M). Data are mean±SEM (n=6 mice/group). Two-way ANOVA followed by post hoc Bonferroni’s test. *p<0.05, **p<0.01 compared with LPC(18:1) + vehicle. (N) Western blot result of pERK, ERK and GAPDH on day 3 in the DRG through the intervention of U0126. (O) Quantitative analysis of expression of pERK on day 3 in the DRG through the intervention of U0126. Data are mean±SEM (n=6 mice/group). Student’s t-test. *p<0.05 compared with LPC(18:1)+vehicle. Red arrows in (E–G, K–M) indicate the time of LPC(18:1) intervention. Black arrows in (E–G, K–M) indicate the time of Go6976 or U0126 administration. ANOVA, analysis of variance; BL, baseline; DRG, dorsal root ganglion; i.t., intrathecal; LPC, lysophosphatidylcholine. Discussion Previously, LPC(18:1) has been reported in the perspective of the chronic metabolic diseases. In this study, we explored the unique role and function of LPC(18:1) in nerve injury-induced NP. First, nerve injury promoted the upregulation of LPC(18:1) in the serum, DRG and CSF, and LPC(18:1) induced pain-like behavior. Next, increased ROS and PLA2 levels facilitated the synthesis of LPC(18:1) in DRG neurons. Finally, GPR132 contributed to the LPC(18:1)-induced NP via PKC-ERK (figure 9). Our findings indicate that LPC(18:1) is expected to be a new biomarker in NP. Illustration of the crosstalk between LPC(18:1) and NP. Augmented oxidative stress and lipid oxidation and upregulation of PLA2 in DRG after nerve injury promote the synthesis of LPC(18:1) in neurons. GPR132 is involved in the SNL/LPC(18:1)-induced neuropathic pain. LPC(18:1) induced the activation of PKC, ERK, and inflammatory factors, which is associated with GPR132 to lead to neuropathic pain. LPC(18:1) is expected to become a biomarker for clinical prediction or treatment of neuropathic pain. DRG, dorsal root ganglion; LPC, lysophosphatidylcholine. A few previous studies have reported that LPC(18:1) accumulated in acute and chronic diseases such as tumors, diabetes, and liver and kidney injury, which were often accompanied by pathological pain.17 Hung et al have demonstrated that fibromyalgia patients had a higher level of LPC(18:1) in the plasma compared with control, in which higher expression of LPC(18:1) showed higher disease severity.12 Our data showed that high concentration of LPC (18:1) in DRG was associated with allodynia and hyperalgesia in mice. Collectively, our animal data and previous clinical evidence suggested that LPC(18:1) would become a biomarker and therapeutic target for predicting chronic pain. i.t. injection of LPC has been used as a novel NP model.18 This was consistent with our results that administration of LPC(18:1) could cause mechanical allodynia and thermal hyperalgesia in mice, but no gender difference. Although sex differences in lipid metabolism were important for chronic diseases, such as arrhythmia-related cardiovascular disease and diabetes-related metabolic disease,19 which may be related to hormone levels. However, specific populations of immune cells in animals, such as microglia, altered pain responses in a sex-specific manner.20 In our study, LPC and its subtypes, as lipid metabolites, could act on various cell types, such as neurons, lymphocytes, macrophages, etc,21 22 without gender preference. Oxidative stress, including the production of hydrogen peroxide and ROS, played a crucial role in NP.23 The initiation of lipid oxidation was regulated by the interaction between polyunsaturated fatty acids and ROS. In response to lipid peroxidation from inflammation and tissue injury, phospholipids underwent lipid peroxidation to LPC.24 Therefore, excessive oxidative stress could cause damage to lipids. Patients with chronic pain were in a higher oxidative state and may be accompanied by an increase of LPC(18:1).13 We certified that the intervention of PLA2 raised the production of LPC(18:1) in primary neurons, not glial cells. This confirmed that the membrane of neurons contained abundant phospholipid libraries, which were abundant for specific lipid messengers synthesized during neuronal stimulation or injury. We found that different injection approach of LPC(18:1) increased the pERK in DRG. PGP9.5, as a neurofiber marker, was not observed a significant increase or decrease on the skin after the injection of LPC(18:1). The target of LPC(18:1) was possibily not be located in the peripheral nerve fibers. It could not affect the membrane structure of peripheral nerves. The surface of DRG neurons was rich in GPCRs or ion channels, and LPC(18:1) was more likely to act on neurons, leading to neuronal excitability and ERK activation. Besides, we also observed that repeat administration of LPC(18:1) induced the activation of microglia and astrocytes in the SC horn. This could be that LPC(18:1) in the DRG affected the neuronal excitability, then molecules released from the neurons were transmitted to the SC, activating astrocyte and microglia. It may also be due to an increase in LPC(18:1) in CSF, directly acting on astrocyte and microglia in the SC via corresponding receptors. Therefore, peripheral and central mechanism of glial activation induced by LPC(18:1) in SC were not be ruled out. The function of LPC was dependent on GPCRs, especially like GPR132.25 T cells overexpressing GPR132 exhibited chemotaxis toward LPC26; GPR132 was also necessary for LPC induced macrophage chemotaxis.27 However, whether and how GPR132 contributes to LPC(18:1)-induced pain were still not well understood. In this study, our research has shown that the increase of GPR132 induced the development and maintenance of LPC(18:1)-induced NP. Blocking GPR132 inhibited the increase of ERK by LPC(18:1). Besides, GPR132 could promote the Gαq subunit to regulate PKC to mediate downstream signaling pathway.28 PKC was probably key molecule mediating the regulation between GPR132 and ERK. In this study, inhibition of PKC alleviated LPC(18:1)-induced NP and downregulated pERK in DRG. Activation of glia cells in the SC horn was induced by LPC(18:1), which was due to that GPR132 has also been reported to be expressed in glial cells.29 Many scholars thought that GPR132 was a receptor for LPC, and LPC directly acted on GPR132 to affect cell growth and immune response27; subsequent experimental results confirmed that GPR132 was indeed an effector of LPC, and the possibility of LPC modifying another receptor to regulate GPR132 could not be ruled out.30 However, whether LPC(18:1) and GPR132 were directly or indirectly involved still needs further exploration. In summary, our investigation delineated the role of LPC(18:1) in the NP. Oxidative stress and lipid oxidation promoted the synthesis of LPC(18:1) in DRG neuron after peripheral nerve injury. GPR132 was involved in LPC(18:1)-induced activation of downstream signaling pathway, which led to NP. LPC(18:1) was expected to become a biomarker for clinical prediction or treatment of NP. Targeting these mechanisms could potentially mitigate NP. Supplementary material Acknowledgements Figure 9 of this paper was created with the aid of BioRender Footnotes Funding: This work is supported by National Natural Science Foundation of China (82071227, 82371217 and 82371216), partly supported by the Key Project of Zhejiang Provincial Natural Science Foundation of China (LZ23H090003), the National Clinical Key Specialty Construction Project of China 2021 (2021-LCZDZK-01) and Leading Health Talents of Zhejiang Province, Zhejiang Health Office No. 18 (2020) Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Ethics approval: The experimental procedures were approved by the Animal Research Committee of the Second Affiliated Hospital, School of Medicine, Zhejiang University (Hangzhou, China) (No. 2022133). This study was conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Data availability free text: The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request. Data availability statement Data are available on reasonable request. References Associated Data Supplementary Materials Data Availability Statement Data are available on reasonable request.